Detrol LA contains the active ingredient tolterodine, a medication used to manage symptoms of overactive bladder. It is available in a 4 mg extended-release pill formulation. In Hong Kong, Detrol LA is a prescription-only product regulated by the Pharmacy and Poisons Board under the Department of Health.
Tolterodine belongs to the antimuscarinic (anticholinergic) class. It blocks the action of acetylcholine at muscarinic receptors in the bladder wall, particularly the M₂ and M₃ subtypes. By reducing involuntary bladder muscle contractions, tolterodine helps increase bladder capacity and reduces urgency, frequency, and urge incontinence. The extended-release formulation allows a steady plasma concentration, providing symptom control throughout the day with once-daily dosing.
Detrol LA is approved for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence in adults. The indication is based on clinical trials demonstrating improvement in urinary episodes and quality-of-life measures. It is not approved for neurogenic bladder or other urinary disorders unless specifically prescribed by a specialist.
No other off-label applications have strong peer-reviewed support at this time.
These effects are usually mild and may improve with continued treatment.
If any of these occur, seek urgent care.
Patients should provide a complete medication list, including over-the-counter drugs and herbal supplements, to their prescriber.
This article provides educational information about Detrol LA and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Take the missed tablet as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take two tablets at once.
Combining antimuscarinics with other bladder-targeting drugs (e.g., β₃-agonists) may increase the risk of urinary retention or other side effects. Any combination therapy should be prescribed and monitored by a specialist.
Anticholinergic effects can reduce tear production, potentially worsening dry-eye symptoms. Patients with pre-existing dry eye should discuss alternatives or close monitoring with their clinician.
The extended-release (ER) formulation releases tolterodine slowly over 24 hours, providing consistent symptom control with once-daily dosing. Immediate-release tablets require multiple doses per day and may cause more peaks and troughs in blood concentration.
Tolterodine does not have a direct effect on blood pressure, but anticholinergic side effects such as dizziness may be more noticeable in patients on antihypertensive therapy. Monitor blood pressure regularly if you have hypertension.
Yes. Keep the medication in its original labeled container, carry a copy of the prescription, and declare it if required by the airline or destination country. For security checks, inform staff that you have a prescribed medication.
Certain herbal products with anticholinergic properties (e.g., belladonna, some antihistamine-containing supplements) may augment side effects. Discuss any supplements you take with your pharmacist.
Detrol LA is a brand name for the 4 mg extended-release formulation. Generic versions contain the same active ingredient and strength but may differ in inactive excipients. Bioequivalence studies confirm they provide comparable therapeutic effects.
Most patients report a reduction in urgency and frequency within 1-2 weeks, with maximal benefit often observed after 4-6 weeks of consistent therapy.
Coverage depends on the individual’s eligibility and the specific public or private health scheme. Patients should verify reimbursement or subsidy options with their health insurance provider or the Hospital Authority.
